<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01876433</url>
  </required_header>
  <id_info>
    <org_study_id>2012-004805-29</org_study_id>
    <nct_id>NCT01876433</nct_id>
  </id_info>
  <brief_title>Beta 3 Agonist Treatment in Heart Failure</brief_title>
  <acronym>Beat-HF</acronym>
  <official_title>Beta 3 Agonist Treatment in Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henning Bundgaard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash Center of Cardiovascular Research, Melbourne, Australia.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Cardiology, Royal North Shore Hospital, Sydney, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: The objective of the study is to assess the structural and functional cardiac
      effects of treatment with the beta 3 AR agonist Mirabegron in patients with chronic heart
      failure.

      Design: We are planning a study aiming at establishing proof of concept that treatment of
      patients with HF with Mirabegron has significant positive effects, as assessed by clinical
      and biochemistry measurements, but not by hard endpoints. We are performing a combined
      dose-finding - chronic efficacy study.

      The study is a randomized, placebo‐controlled, double‐blinded trial. The follow‐up period is
      6 months. 70 patients with chronic heartfailure will be included.

      Specific aims

        1. Determine safety of administration of Mirabegron to patients with heart failure.

        2. Determine if treatment with Mirabegron for 6 months induces beneficial cardiac
           structural remodelling in patients with heart failure.

        3. Determine if Mirabegron improves symptoms and exercise capacity as indicated by
           questionnaires and 6 min walk test in patients with heart failure.

        4. Determine effects of Mirabegron on cardiac conduction, repolarisation and rhythms and
           arrhythmias in patients with heart failure.

        5. Determine effects of Mirabegron on circulating biomarkers in patients with heart
           failure.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increase in LVEF (measured by MRI or CT)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>A reduction in NT proBNP</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An increase in 6 min walking distance</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An increase in CO/SV</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A reduction in LVIDd</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>An improvement in diastolic function</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A reduction in LA volume</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A reduction in LV diameters</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A shortening of the QT interval</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in quality of life</measure>
    <time_frame>6 monhs</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in functional class</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)</condition>
  <arm_group>
    <arm_group_label>Beta-3-agonist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mirabegron 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 25 mg x 2 titrated up to maximal tolerated dosis or a maximum of 150 mg x 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirabegron</intervention_name>
    <arm_group_label>Beta-3-agonist</arm_group_label>
    <other_name>Beta 3 agonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Stable heart failure NYHA class II-III on ischemic or non-ischemic basis

          2. Left ventricular ejection fraction (LVEF) &lt; 40%

          3. Stable sinus rhythm (SR)

          4. On optimised evidence-based pharmacological HF treatment stable &gt; 4 weeks with no
             current plan for changing HF therapy. The therapy must include a beta-blocker.

          5. No change in diuretics &lt; 4 weeks

          6. &gt;18 years

        Exclusion Criteria:

          1. Unstable cardiac condition

          2. Acute myocardial infarction (AMI) or revascularisation &lt; 3 month ago

          3. Atrial fibrillation (for technical reasons in relation to imaging and HR reporting)

          4. Uncorrected significant primary obstructive valve disease

          5. Planned major surgery including cardiac revascularisation

          6. Hemodynamically significant obstructive cardiomyopathy

          7. Stroke with significant neurological deficit

          8. Acute myocarditis or constrictive pericarditis

          9. Symptomatic bradycardia or &gt; 1. degree AV-block unless the patient has a pacemaker

         10. Clinically significant hepatic (transaminases or bilirubin x 3 above upper reference
             level) or renal (GFR&lt; 50 ml/min/1,73 m2) diseases

         11. Heart failure due to uncorrected thyroid disease

         12. Cardiac mechanical support

         13. &lt; 6 months after CRT

         14. Uncontrolled hypotension (defined as symptomatic systolic blood pressure &lt; 90 mmHg) -
             or hypertension (defined as systolic at 180 mmHg or above and/or diastolic blood
             pressure at 110 mmHg or below)

         15. Body mass index (BMI) &gt; 35

         16. Unable to give informed consent

         17. Reduced compliance

         18. All women of child bearing potential will be required to use adequate contraception

         19. Pregnant or lactating women

         20. Treatment with a tricyclic antidepressant or CYP2D6 substrates other than
             beta-blockers or treatment with digoxin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Bundgaard, MD, PhD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet Copenhagen University Hospital, Department of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henning Bundgaard, MD, DMSci</last_name>
    <phone>+4535450512</phone>
    <email>henningbundgaard@dadlnet.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Monash Center of Cardiovascular Research.</name>
      <address>
        <city>Melbourne</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henry Krum, MD, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Henry Krum, MD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Royal North Shore Hospital.</name>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helge Rasmussen, MD, Professor</last_name>
    </contact>
    <investigator>
      <last_name>Helge Rasmussen, MD, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, The Heart Centre, Rigshospitalet Copenhagen University Hospital.</name>
      <address>
        <city>Copenhagen Ø</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henning Bundgaard, MD, DMSci</last_name>
      <phone>+4535450512</phone>
      <email>henningbundgaard@dadlnet.dk</email>
    </contact>
    <investigator>
      <last_name>Henning Bundgaard, MD, PhD, DMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2013</study_first_submitted>
  <study_first_submitted_qc>June 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2013</study_first_posted>
  <last_update_submitted>June 9, 2015</last_update_submitted>
  <last_update_submitted_qc>June 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Henning Bundgaard</investigator_full_name>
    <investigator_title>Consultant, dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mirabegron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

